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Abstract Pulmonary arterial hypertension (PAH) is a
fatal disease for which no cure is yet available. The leading
cause of death in PAH is right ventricular (RV) failure.
Previously, the TNF receptor superfamily member fibro-
blast growth factor-inducible molecule 14 (Fn14) has been
associated with different fibrotic diseases. However, so far
there is no study demonstrating a causal role for endoge-
nous Fn14 signaling in RV or LV heart disease. The pur-
pose of this study was to determine whether global ablation
of Fn14 prevents RV fibrosis and remodeling improving
heart function. Here, we provide evidence for a causative
role of Fn14 in pulmonary artery banding (PAB)-induced
RV fibrosis and dysfunction in mice. Fn14 expression was
increased in the RV after PAB. Mice lacking Fn14
(Fn14-/-) displayed substantially reduced RV fibrosis and
dysfunction following PAB compared to wild-type litter-
mates. Cell culture experiments demonstrated that activation
of Fn14 induces collagen expression via RhoA-dependent
nuclear translocation of myocardin-related transcription
factor-A (MRTF-A)/MAL. Furthermore, activation of Fn14
in vitro caused fibroblast proliferation and myofibroblast
differentiation, which corresponds to suppression of PAB-
induced RV fibrosis in Fn14-/- mice. Moreover, our findings
suggest that Fn14 expression is regulated by endothelin-1
(ET-1) in cardiac fibroblasts. We conclude that Fn14 is an
endogenous key regulator in cardiac fibrosis and suggest this
receptor as potential new target for therapeutic interventions
in heart failure.
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Introduction
Pulmonary arterial hypertension is a fatal disease with a
3-year mortality rate of 20–40 % for which no cure is
available [12, 18, 43]. During disease progression, the RV
undergoes compensatory hypertrophy to maintain physio-
logical blood pressure and flow. As PAH progresses the RV
becomes fibrotic and dilates and ultimately undergoes
functional failure [8, 38]. In recent years, the outlook for
PAH patients has improved due to earlier recognition and
new therapies. However, despite these interventions vas-
cular pulmonary resistance was high and increased over
time leading eventually still to RV failure [8, 41]. Thus, it
is important to elucidate mechanisms driving RV remod-
eling and transition to RV dysfunction to identify new
targets for therapeutic intervention [47].
Previously, the receptor Fn14 and its ligand TWEAK
have been associated with LV remodeling after myocardial
infarction (MI) [6, 33]. Systemic overexpression of
TWEAK induced via Fn14 progressive dilated cardiomy-
opathy and heart failure affecting both the LV and RV [20].
This phenotype was associated with cardiomyocyte elon-
gation and cardiac fibrosis. Fn14 is also expressed in
human cardiomyocytes and circulating TWEAK levels
were correlated with idiopathic dilated cardiomyopathy
[20]. In contrast, TWEAK levels were inversely correlated
with the severity of PAH in patients suggesting that the
TWEAK/Fn14 axis might play no role in the RV failure
[11]. However, correlations of cytokine blood levels to
heart disease can be misleading. For example, TNF over-
expression leads to heart failure and its endogenous
expression is positively correlated with heart failure [23].
However, clinical trials with anti-TNF therapies were dis-
appointing [27]. Moreover, as with PAH, TWEAK blood
plasma levels are decreased in patients and animal models
with chronic kidney disease (CKD). In contrast, Fn14 is
upregulated in the kidney in animal models as well as
patients with CKD [19, 52]. Deletion of Fn14 in the animal
models protects against kidney fibrosis and failure [19].
Thus, it is important to study the endogenous role of Fn14
in heart disease.
TWEAK plays an important role in several biological
processes including inflammation, angiogenesis, cell
growth, cell death and fibrosis. Depending on cell type and
context TWEAK mediates these activities via Fn14 by
activating a variety of downstream signaling cascades. Our
previous data have suggested that TWEAK-induced car-
diomyocyte proliferation is mediated through activation of
ERK and PI3K as well as inhibition of GSK-3beta [35].
Recently, NFjB has been identified as a major downstream
target of the TWEAK/Fn14 axis through functional vali-
dation in numerous cellular and invivo contexts [31]. With
regard to signaling in heart cell types, the TWEAK/Fn14
axis was shown to induce NFjB signaling in cardiomyo-
cytes [6] as well as fibroblasts [5].
Here we examined Fn14 expression in models of pres-
sure overload (3 weeks after PAB in mice [2, 3] or mon-
ocrotaline (MCT) treatment of rats [7, 26]) and found Fn14
markedly upregulated in the RV. Fn14-/- mice exhibited
reduced fibrosis and improved RV function following PAB.
Our data show that Fn14 activation regulates fibroblast
proliferation, differentiation and collagen expression.
Finally, our data suggest a novel TWEAK/Fn14/RhoA/
MAL pathway downstream of ET-1 signaling in cardiac
fibroblasts (CFs). Collectively, our data demonstrate that
Fn14 is an important endogenous mediator of RV remod-
eling and failure.
Methods
An expanded version of methods is available in Supple-
mentary material online.
Animal studies
The investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the Directive
2010/63/EU of the European Parliament. In vivo proce-
dures were approved by a local Animal Ethics Committee
in accordance to governmental and international guidelines
on animal experimentation. Fn14-/- mice were previously
generated at Biogen (Biogen Idec, Inc, Cambridge) [21].
PAB and/or SHAM operation of mice (20–23 g) was per-
formed under isoflurane anesthesia (1.5 % v/v) and
0.03 mg/kg buprenorphine hydrochloride (s.c.). Analgetic
therapy post operation was achieved by buprenorphine
(0.03 mg/kg, 48 h) and carprofen (s.c., 4 mg/kg, 3–7 days).
Pulmonary hypertension in Sprague–Dawley rats
(300–350 g) was induced with 60 mg/kg MCT (s.c.) [42].
Animals were daily controlled for signs of pain. Functional
analyses were performed by MRI and hemodynamic mea-
surements with a Millar microtip catheter under inhalation of
isoflurane (1.5–2.0 % v/v). For organ/tissue sampling, ani-
mals were anesthetized (120 mg/kg ketamine ? 16 mg/kg
xylazine) and subsequently euthanized through exsanguina-
tion. Blood was intracardially collected and analyzed with a
RayBio_Mouse TWEAK ELISA Kit.
Cell culture experiments
Cardiac fibroblasts were isolated with Liberase TH enzyme
mix (Roche) from Fn14-/- mice and wild-type littermates.
All experiments were performed with primary CFs after
one or two passages. As an immortalized fibroblast cell line
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the Rat2 fibroblast cell line was used; a normal, non-
tumorigenic and highly transfectable cell line derived from
the Fischer rat fibroblast 3T3 like cell line Rat1. HEK293T
cells were utilized for luciferase reporter assays. NIH3T3
cells were used as control cells for MAL nuclear translo-
cation assays. Cells were cultured under standard condi-
tions or as indicated.
Construction of pEGFP-TWEAK
TWEAK cDNA was amplified from HEK293T cells,
ligated into pGEM-T-easy and a HindIII/SalI TWEAK
fragment was subcloned into pEGFP-N1.
Transfection and luciferase promoter assays
Transient transfections were performed with Fugene 6
(Roche) with a total of 50 ng of constructs. Luciferase
activity was measured by LightSwitch Luciferase Assay
Reagent after 24 h of stimulation or 30–48 h after
overexpression.
Western blot
Tissues were lysed and homogenized in RIPA buffer.
Protein extracts were resolved on SDS gels, blotted on
nitrocellulose membranes and incubated with the following
primary antibodies: rabbit anti-TWEAK/Fn14 receptor,
rabbit anti-pan-actin, monoclonal rabbit anti-RhoA
(1:1,000) (all cell signaling), goat anti-DDR2 (Santa Cruz),
rabbit anti-Collagen Type 1 (1:500) (Rockland Immuno-
chemicals), mouse anti-GAPDH (1:2,000) (Sigma) and
polyclonal rabbit anti-MAL (1:200) (from G. Posern). Anti-
gen–antibody complexes were visualized using horseradish
peroxidase-conjugated secondary antibodies. Western blots
were quantified by Image J (NIH) software.
siRNA-mediated knockdown of MAL
Cardiac fibroblasts from wild-type mice were split in serum-
free medium and 24 h later transfected with 40 pM of siRNA
perfectly matching the sequence 50-ATGGAGCTGGTG
GAGAAGAA-30 of both murine MAL and MRTF-B and
40 pM of scrambled siRNA (Qiagen) with lipofectamine
[30]. 24 h later cells were stimulated with 100 ng/ml of
TWEAK.
Determination of activated RhoA
Activated RhoA was determined by immunoprecipitation
with the fusion protein GST-Rho-binding domain of
Rhotekin (GST-RBD) [39].
RNA extraction and Real-Time PCR
RNA was isolated with an RNeasy Fibrous Tissue Kit. RT
reaction was performed using oligo (dT) primer. For Real-
Time PCR analysis, cDNA was amplified with IQTM
SYBR Green SuperMix (Biorad) and Bio-Rad iCYCLER
iQ5. Real-Time PCR was performed in triplicates and
relative gene expression was calculated on the basis of DCt
values to gapdh.
Immunohistochemistry
Mouse hearts were isolated, dissected in RV and LV ? S,
washed in PBS, fixated overnight in 10 % PFA, embedded
in paraffin and sectioned longitudinally (5 lm). Sections
were deparaffinized in xylene and rehydrated in ethanol.
Heat-mediated antigen retrieval was performed in 0.05 M
EDTA buffer (pH 8.0). Tissues for cryosections (5 lm)
were frozen in OCT, fixated in acetone and stained as
indicated. To quantify fibrosis RV sections were stained
with 0.1 % Sirius Red F3B in picric acid and analyzed
using a QWin V3 computer-assisted image analysis soft-
ware (Leica) [15].
Immunofluorescence
Heart sections were blocked in 5 % goat serum/0.2 %
Tween-20/PBS for 1 h at RT. Cells were fixated in 3.7 %
paraformaldehyde and permeabilized in PBS/0.5 % Triton.
Samples were stained as indicated. F-actin was detected by
rhodamine–phalloidin and cell membranes by WGA
staining (Molecular Probes, Invitrogen). Cell size was
determined using the ImageJ (NIH) software.
Endothelin stimulation
After serum starvation cells were stimulated for 24 h with
100 nM ET-1 (R and D systems).
Collagen assay
Serum-starved Rat2 fibroblasts were stimulated with
TWEAK (100 ng/ml) for 48 h. L-ascorbic acid (0.25 mM)
was added to the medium daily. Cells were lysed in RIPA
buffer and total collagen (Types 1–5) was assessed using a
Sircol soluble collagen assay kit (Biocolor Ltd).
MAL translocation
MAL translocation was determined with the Count soft-
ware (by B. Waclaw). Nuclei number was assessed based
on DAPI staining. MAL translocation was considered
positive if the pixel number in the purple channel
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(MAL/DAPI overlap) was greater or equal compared to the
threshold defined by control experiments.
Proliferation assay
Proliferation was determined with a CountessTM cell
counter (Invitrogen) or CellTiter 96 Aqueous Cell Prolif-
eration Assay (Promega).
Statistical analyses
Data were analyzed with GraphPad Prism. Data are pre-
sented as mean ± standard error of the mean (SEM). Sta-
tistical significance was determined using Student’s t test
or for multiple comparisons One-way ANOVA followed
by Bonferroni’s post hoc test. Values of p \ 0.05 were
considered statistically significant.
Results
Fn14 expression is upregulated in models of RV failure
To assess whether Fn14 signaling is involved in RV failure,
we determined the expression levels of Fn14 in RVs
3 weeks after PAB in mice by Real-Time PCR. LVs were
used as an internal control as they are not affected in this
model. Fn14 mRNA expression was not upregulated in
LVs (Fig. 1a). In contrast, Real-Time PCR analyses uti-
lizing primers spanning the TWEAK-binding (exon 1–2),
transmembrane (exon 2–3, only present in full-length) and
TRAF-binding cytosolic (exon 3–4) motifs of Fn14 dem-
onstrated upregulated expression of full-length Fn14
(NM_013749.2) in RVs of mice after PAB (Fig. 1a). A
correlation between RV dysfunction and Fn14 expression
was confirmed at protein level after PAB (Fig. 1b, c). In
contrast to TWEAK, Fn14 was strongly expressed
throughout the diseased RV (Fig. 1d and Supplemental
Fig. 1a). Co-staining experiments indicated that Fn14
expression is upregulated in cardiomyocytes and fibroblasts
(Fig. 1e, f). This was further supported by Western blot
analyses of RV mouse CFs after PAB (Fig. 1g). Taken
together our data suggest a positive correlation between
upregulation of Fn14 in the heart and RV failure.
Previously, it has been determined that TWEAK levels
are inversely correlated with the severity of PAH in
patients. This observation led to the conclusion that the
TWEAK/Fn14 axis may have no role in RV disease [11].
In contrast to the observation in humans, TWEAK levels
were unchanged in PAB-operated animals (Supplemental
Fig. 1b). To further investigate this controversy we utilized
a second RV disease model MCT treatment in rats. Neither
Fn14 nor TWEAK mRNA expression was upregulated in
LVs. In contrast, Fn14 and TWEAK mRNA expression
were markedly upregulated in RVs after MCT treatment
(Supplemental Fig. 1c, d). In contrast, TWEAK blood
plasma levels were significantly reduced (Supplemental
Fig. 1e). Thus, TWEAK blood plasma levels do not nec-
essarily correlate with the expression levels of TWEAK
and/or Fn14 in the heart.
Fn14-/- mice are resistant to PAB-induced RV
dysfunction
To evaluate a causative role of Fn14 upregulation and RV
failure, we challenged wild-type Fn14?/? and knockout
Fn14-/- mice with PAB and analyzed RV function. Under
physiological conditions, no significant differences were
observed. A consistent increase in systolic RV pressure in
Fn14?/? as well as Fn14-/- PAB-operated mice confirmed
proper banding (Fig. 2e). After PAB, Fn14?/? mice
exhibited dramatic increases in RV end-systolic volume
(ESV) and end-diastolic volume (EDV), indicating dilation
and a decrease in RV ejection fraction (EF). In contrast,
Fn14-/- mice were resistant to RV dilation showing a
significantly better RV EF after PAB (Fig. 2 and Supple-
mental Table S1). In conclusion, these results indicate that
Fn14 is a potent endogenous mediator of RV dysfunction
and that deletion of Fn14 protects mice from PAB-induced
RV dysfunction.
Fn14 signaling regulates fibrosis
Three weeks post-PAB, the fibrotic area was reduced by
39 % fibrosis in RVs of Fn14-/- mice compared to Fn14?/?
littermates (Fig. 3a, b). Moreover, PAB-induced upregula-
tion of fibrosis-associated collagen genes like Col1a1 and
Col1a2 was diminished (Fig. 3c–e). Expression levels of
collagens were not affected in the LV (data not shown).
These data suggest that Fn14 is an endogenous mediator of
fibrosis in RV heart disease.
Fn14 signaling regulates collagen expression
via the RhoA-Mal axis
To further understand Fn14 signaling with regards to
fibrosis, we utilized cell lines and primary CFs expressing
Fn14 endogenously (Fig. 4 and Supplemental Fig. 2a).
HEK293T cells were utilized as standard cell type for
luciferase promoter assays. TWEAK treatment of
HEK293T cells markedly enhanced Col1a1 and Col1a2
promoter activity (Fig. 4a, b). To determine collagen syn-
thesis, we utilized the Rat2 fibroblast cell line, as
HEK293T are suboptimal for such studies [34]. TWEAK
treatment of Rat2 fibroblasts resulted in the accumulation
of collagens, which was abolished by co-treatment with
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ITEM2, an Fn14 blocking antibody (Fig. 4c and Supple-
mental Fig. 2b, c). Importantly, TWEAK treatment also
enhanced collagen expression by primary CFs of Fn14?/?
mice, but had no effect on CFs of Fn14-/- mice (Fig. 4d).
Collectively, we conclude that Fn14 regulates collagen
expression in fibroblasts.
It has been demonstrated that the transcription factor
MAL plays a regulatory role in collagen expression. Fur-
thermore, it has been shown that the Col1a2 promoter is a
direct target of MAL [44] and that serum stimulation of
NIH3T3 cells induces MAL nuclear translocation [32]. To
determine if the TWEAK/Fn14 axis promotes MAL
nuclear translocation NIH3T3 cells and primary Fn14?/?
CFs were stimulated with TWEAK. As a positive control
we used 15 % serum. Stimulation of Fn14?/? CFs with
TWEAK resulted in nuclear translocation of MAL (Fig. 4e
and Supplemental Fig. 3a, b), which was inhibited in
Fn14-/- CFs (Fig. 4e). In addition, MAL overexpression
enhanced TWEAK-induced Col1a2 promoter activity in
HEK293T cells (Fig. 4f). Finally, siRNA-mediated knock-
down of MAL abolished TWEAK-induced collagen
expression (Supplemental Fig. 2d, e). These results suggest
that Fn14 activation promotes collagen expression via
induction of MAL nuclear translocation.
MAL is regulated through the Rho GTPase-actin pathway
[32]. Activation of RhoA determined by a Rhotekin pull
down assay was first established in HEK293 cells (Supple-
mental Fig. 3c). TWEAK stimulation of primary Fn14?/?
CFs but not of Fn14-/- CFs led to strong RhoA activation
(Fig. 4g). Moreover, MAL translocation to the nucleus could
be suppressed by inhibitors to ROCK kinase (Y27632) or the
Rho/SRF pathway (CCG-1432) in NIH3T3 cells (Fig. 4h).
These results indicate that TWEAK can promote MAL











































































































Fig. 1 Fn14 expression in RV heart disease. a Real-Time PCR
analyses of Fn14 mRNA expression from RV demonstrated elevated
expression following PAB. No significant changes were observed in
LVs (*p \ 0.05, n = 4). Loading control: gapdh. b Western blot
analysis of RV extracts of WT, SHAM- and PAB-operated mice
showing a prevalent expression of Fn14 after PAB in RV. No
significant difference was observed for TWEAK. Loading control:
Pan-actin. c Quantitative analysis of b. Fn14 levels (normalized to
pan-actin) of four individual hearts per condition were expressed as
arbitrary units ± SEM. d Immunohistochemistry: Fn14 protein
expression is elevated after PAB in RV of Fn14?/? animals. Nuclei
were counterstained with methyl green. Sections from Fn14-/- mice
served as control for the specificity of the used anti-Fn14 antibody.
e and f Co-staining experiments with fibroblast-markers (e, DDR2; f,
P4HB: prolyl 4-hydroxylase, beta polypeptide) indicating that Fn14
expression is upregulated in fibroblasts after PAB in RV of Fn14?/?
animals. Arrows: Fn14-positive fibroblasts. Stars: cardiomyocytes.
g Western blot analysis: Fn14 is upregulated in isolated Fn14?/? CFs
from RVs after PAB. Scale bars: 65 lm. RV right ventricle, LV left
ventricle, PAB pulmonary artery banding
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ET-1 regulates Fn14
ET-1 is an important player in the pathogenesis of PAH.
Upregulation of ET-1 in patients is associated to PAH [46] and
cardiac fibrosis [36]. Its blood level is upregulated after PAB
in mice [13, 37] and in PAH patients [14]. Thus, we suspected
that ET-1 might be responsible for the upregulation of Fn14
upon PAB. As hypothesized, PAB resulted in the upregulation
of ET-1 in wildtype Fn14?/? mice (Fig. 4i). Importantly,
exposure of primary CFs to ET-1 resulted in marked upreg-
ulation of Fn14 expression (Fig. 4j). Finally, ET-1 stimulation
significantly enhanced TWEAK-induced nuclear MAL
translocation in Fn14?/? CFs, but not Fn14-/- CFs (Fig. 4k).
In conclusion, our data suggest that ET-1 enhances signaling
through the Fn14-RhoA-MAL axis inducing collagen
expression and thereby promoting RV fibrosis.
Fn14 signaling promotes myofibroblast differentiation
Another characteristic upon tissue injury besides collagen
expression is the differentiation of interstitial fibroblasts into
myofibroblasts, which are characterized by the expression of
smooth muscle cell (SMC) markers. As the SRF co-activator
MAL is also critical for the induction of the myofibroblast-
associated genes a-smooth muscle actin (SMA) and
a-smooth muscle protein 22 (SM22), we analyzed Fn14-/-
mice for defects on myofibroblast differentiation [44].
Expression of SMA and SM22 was attenuated in RVs of
Fn14-/- animals after PAB (Fig. 5a, b). However, as SMA is
expressed in spindle-shaped myofibroblasts as well as
smooth muscle cells in blood vessels, we performed immu-
nofluorescence stainings. We detected in Fn14-/- RVs sig-
nificantly lower numbers of spindle-shaped SMA-positive
myofibroblasts, which were not associated with any vessel
(Fig. 5c). Importantly, TWEAK stimulation induced the
accumulation of organized stress fibers, a hallmark of
myofibroblasts, in Rat2 fibroblasts (Supplemental Fig. 3d)
as well as in Fn14?/? CFs, but not Fn14-/- CFs (Fig. 5d).
These data identify Fn14 as a potential mediator of myofi-
broblast differentiation.
Fn14 regulates fibroblast proliferation
Enhanced fibroblast proliferation can also contribute to
alteration of connective tissue homeostasis and fibrosis
under pathophysiological conditions [44]. Quantification of
staining of the proliferation marker proliferating cell
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Fig. 2 Fn14-/- mice show improved heart function after PAB. MRI
imaging. a RV ejection fraction (EF) before PAB was not
significantly different between wild-type and knockout mice (SHAM:
Fn14?/?: n = 4; Fn14-/-: n = 6; PAB-operated mice: n = 11 both
for Fn14?/? and Fn14-/-). b RV EF was markedly decreased
3 weeks after PAB in Fn14?/? mice (n = 11, ***p \ 0.0001).
Reduction of RV EF was significantly inhibited in Fn14-/- mice
(n C 4 for SHAM-operated mice; n = 11 for PAB-operated mice,
*p \ 0.05). c End-diastolic (ESV) and EDVs (*p \ 0.05, n = 11 for
PAB-operated mice). d Representative MRI images of hearts from
SHAM- and PAB-operated mice. ED end-diastole, ES end-systole.
e Peak of RV systolic pressure. RV right ventricle, PAB pulmonary
artery banding. LVs are indicated by arrows, RVs by arrowheads
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cardiomyocyte proliferation after PAB (data not shown).
There was, however, a trend towards decreased prolifera-
tion of interstitial cells corroborating with a diminished
interstitial cell density in Fn14-/- hearts (Fig. 6a, b).
Quantification showed that the total number of interstitial
cells was significantly higher in RVs from Fn14?/? animals
compared to Fn14-/- littermates (Fig. 6c). Immunofluo-
rescence analyses with the fibroblast-specific marker dis-
coidin domain receptor 2 (DDR2) revealed that the major
cell type in the interstitial cell clusters is fibroblasts
(Fig. 6d). These data suggest that fibroblast proliferation
was decreased in the absence of Fn14.
To directly address whether TWEAK/Fn14 signaling is
sufficient to induce fibroblast proliferation, Rat2 cells and
CFs ([90 % fibroblasts, Supplemental Fig. 4a) were
stimulated with TWEAK in serum-free medium. TWEAK
stimulation induced Rat2 fibroblast proliferation in a con-
centration-dependent manner. Fn14 overexpression by
itself resulted in proliferation in serum low conditions
(Supplemental Fig. 4b–d). Importantly, in vitro TWEAK
stimulation of CFs enhanced proliferation of Fn14?/? but
not of Fn14-/- CFs (Fig. 6e) supporting the notion that the
TWEAK/Fn14 axis regulates fibroblast proliferation.
Taken together, these results indicate that the protective
effect of Fn14 deletion could be explained in part by the
impact of Fn14 activation on fibroblast proliferation, dif-
ferentiation and collagen expression (Fig. 6f).
Discussion
The development of RV failure involves complex patho-
logical mechanisms whereas identification of underlying
causes and successful medical treatment remain a major
challenge. Here, we show that Fn14 deletion reduces
markedly PAB-induced right heart fibrosis and dysfunc-
tion. Our data provide strong evidence that inhibition of
endogenous TWEAK/Fn14 pathway may potentially be
clinically beneficial in treating right heart disease due to
pressure overload. This is important as right heart disease is
poorly characterized with limited treatment options. Fur-












































































































Fig. 3 Fn14 ablation reduces
myocardial fibrosis after PAB.
a Sirius Red staining
demonstrating attenuation of
RV fibrosis 3 weeks after PAB
in Fn14-/- mice. Scale bars:
300 lm. b Quantitative analysis
(SHAM: Fn14?/? and Fn14-/-:
n = 4, PAB: Fn14?/?: n = 5,
Fn14-/-: n = 7, *p \ 0.05).
c–f Real-Time PCR
demonstrating that upregulation
of Col1a1, Col1a2, Col3a1 and
Col4a1 expression in RVs after
PAB was diminished in
Fn14-/- mice. Expression
levels were normalized to gapdh
(**p \ 0.005, *p \ 0.05,
n = 4). RV right ventricle,
PAB pulmonary artery banding
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Fig. 4 Fn14 signaling regulates collagen expression via the RhoA-
Mal axis. (a and b) Luciferase reporter assays reveal that TWEAK
stimulation activates Col1a1 and Col1a2 promoter (n = 7,
**p \ 0.01). HEK293T cells were transfected with indicated pro-
moter constructs and 24 h later stimulated with TWEAK. c Western
blot analysis of TWEAK-stimulated Rat2 fibroblasts showing mark-
edly upregulated Collagen I expression. d TWEAK-induced produc-
tion of collagens in CFs depends on Fn14 (n = 4, TWEAK versus
serum-free, Fn14?/?: *p \ 0.05; Fn14-/-: not significant).
e TWEAK-induced nuclear translocation of MAL in cardiac fibro-
blasts depends on Fn14. Arrows indicate MAL-negative nuclei.
Arrowheads indicate MAL-positive nuclei. Scale bars: 50 lm.
f Promoter assays in HEK293T revealed enhancement of Col1a2
promoter activation after MAL and TWEAK overexpression. pEGFP-
N1 (pEGFP) was used as control plasmid. g Amount of activated
RhoA determined by immunoprecipitation with Rho-binding domain
of Rhotekin (GST-RBD) in Fn14?/? and Fn14-/- CFs. h Pre-
incubation of NIH3T3 cells with ROCK kinase inhibitor Y27632
(20 lM) [*p \ 0.05 vs. DMSO (control)] and CCG-1432 (5 lM)
[**p \ 0.005 vs. DMSO (control)] inhibited TWEAK-induced
nuclear MAL translocation (n = 3). RV right ventricle, PAB
pulmonary artery banding. (I) Real-Time PCR revealed a significant
increase in ET-1 levels in RVs following PAB in wildtype Fn14?/?
mice. Loading control: gapdh (n [ 3, *p \ 0.05). j Western blot
analysis: ET-1 (100 nM) induces Fn14 expression in Fn14?/? CFs
(n = 3). k Co-stimulation with TWEAK/ET-1 markedly induced
MAL translocation in Fn14?/? CFs compared to ET-1 (*p \ 0.01)
and TWEAK stimulation alone (*p \ 0.05) (four mice per each
group, n = 4)
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mechanistic level with the MAL-collagen pathway and
provides evidence that Fn14 itself is regulated by ET-1.
It has previously been shown that inhibition of Fn14
signaling reduces fibrotic processes in several organs in
disease models [19, 51, 53, 54]. In the heart, this pathway
has been associated with LV remodeling. Systemic over-
expression of TWEAK induced heart failure affecting LV
and RV [20]. However, it remained unclear whether
endogenous TWEAK/Fn14 signaling plays an active role in
cardiac remodeling. Decreased TWEAK blood levels in
patients with PAH argue against a role in the RV [11].
However, reduced TWEAK blood levels might be due to
sequestration of circulating TWEAK by the upregulated
Fn14 receptor or might be a compensatory mechanism to
protect from the consequences of Fn14 activation. This is
supported by our findings that TWEAK blood plasma
levels were reduced in MCT-treated rats while Fn14 was
upregulated in the heart. In fact, opposite to most other
signaling principles, in vivo TWEAK/FN14 pathway acti-
vation is regulated by changing the concentration of the
receptor, not of the ligand, [1]. Moreover, high Fn14 levels
are reported to activate downstream signaling with few or
none TWEAK present [50]. Finally, correlations of cyto-
kine blood levels to heart disease can be misleading as
exemplified by TNF [27]. Interestingly, TWEAK blood
plasma levels are also decreased in patients and animal
models with CKD whereas Fn14 was upregulated in the
kidney. Importantly, deletion of Fn14 in the animal models
protects against kidney fibrosis and failure [19, 52].
Fibrosis is characterized by fibroblast accumulation and
excess deposition of extracellular matrix proteins, which
leads to tissue remodeling and dysfunction. The traditional
view is that the underlying mechanism is induction of
resident fibroblast proliferation [24]. Our data suggest that
reduced RV fibrosis upon PAB in Fn14-/- mice is partially
due to inhibition of this process. This is in accordance with
reports that TWEAK has pro-mitogenic effects on cardiac
cells including fibroblasts [5, 28, 35]. Thus, reduced
numbers of myofibroblasts and fibrosis might be due to
reduced fibroblast proliferation. However, as the activation
of TWEAK/Fn14 signaling was sufficient to induce myo-
fibroblast differentiation and collagen expression in vitro, it
appears likely that induced Fn14 re-expression also pro-
motes myofibroblast differentiation driving RV fibrosis.
The traditional view of fibrosis has been challenged
during the last years as it became clear that the fibroblast
population exhibits a large phenotypic heterogeneity [24].
It is now clear that fibroblasts can be derived from endo-
thelial cells, pericytes, bone marrow-derived progenitor
cells, monocytes, and fibrocytes. Thus, it is possible that
inhibition of TWEAK/Fn14 signaling is not only regulating
fibroblasts proliferation and collagen expression but also
fibroblast precursor recruitment. Whether this plays in
PAB-induced fibrosis a major role is unknown. However, it
is well known that the TWEAK/Fn14 axis affects the
immune response upon tissue injury [4] and it has been
hypothesized that it induces the recruiting of proinflam-
matory mediators during the acute phase of MI while at
later time points, it participates in extracellular matrix
remodeling and fibrosis. Therefore, it will be interesting to
determine in future experiments whether TWEAK/Fn14
controls fibroblast precursor recruitment in the PAB model.
Although our in vitro data indicate that TWEAK can
modulate directly fibroblast proliferation, differentiation and
collagen synthesis, we cannot conclude from our data whe-























































































Fig. 5 Fn14 regulates
myofibroblast differentiation.
(a and b) Real-Time PCR
revealed a significant reduction
of SM22 and SMA induction in
RVs of Fn14-/- PAB-operated
mice. Loading control: gapdh
(n = 4, *p \ 0.05).
c Quantification of SMA-
positive myofibroblasts (four
mice per group, *p \ 0.05).
d TWEAK stimulation resulted
in the enrichment of actin fibers
(Rhodamine-phalloidin, red) in
Fn14?/?, but not Fn14-/- CFs.
Scale bars: 50 lm
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effect or due to an unknown systemic, e.g. immune-mediated
effect as we have utilized a general knockout model. Future
studies utilizing conditional knockout mice will elucidate the
underlying cellular mechanism.
SM22 and SMA both contain CArG boxes in their
transcription control region, which are known targets of
actin-MAL/MRTF-SRF signaling [9, 44, 49]. MAL directly
regulates Col1a2 gene expression [44]. It is a downstream
target of Rho GTPase-actin signaling, which targets ROCK
and MLC kinases [32]. Nuclear MAL translocation links
reorganization of the actin cytoskeleton to SRF-dependent
gene transcription and myofibroblast differentiation [16, 25,
44]. Finally, ROCK inhibition can reduce cardiac fibrosis
[16, 17, 40]. In accordance with these data, TWEAK stim-
ulation led to rapid activation of RhoA kinase in CFs.





























































































































Fig. 6 Fn14 regulates fibroblasts proliferation. a Quantitative anal-
ysis of PCNA-positive interstitial cells after PAB (Fn14?/?: 6 and,
Fn14-/-: seven mice per group). b Representative examples of
stained heart sections used to determine interstitial nuclear density.
Scale bars: 100 lm. c Quantification of b (Fn14?/?: six mice and
Fn14-/-: seven mice per group, **p \ 0.005, ***p \ 0.0001).
d Immunofluorescence analyses: the majority of cells in the clusters
are fibroblasts (DDR2). Red arrow: fibroblasts. Yellow arrows: non-
fibroblast interstitial cells. Scale bars: 25 lm. e TWEAK increased
the number of Fn14?/?, but not Fn14-/- CFs in a dosage-dependent
manner (n = 5, **p \ 0.001). f Proposed model of TWEAK/Fn14
axis activity during RV fibrosis. RV right ventricle, PAB pulmonary
artery banding
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nuclear MAL translocation and reduced collagen expression.
Our data suggest that TWEAK activates via Fn14 the RhoA-
ROCK-dependent nuclear translocation of MAL to trigger
SRF-dependent transcription. As Chen and co-workers have
recently demonstrated that TWEAK/Fn14 signaling pro-
motes proliferation and collagen synthesis of rat CFs via the
NF-rB pathway it will be interesting to determine in the
future how these pathways interact [5, 48, 55].
Fn14 expression itself can be induced in CFs by ET-1,
one of the key regulators implicated in the pathogenesis of
PAH [45]. Importantly, ET-1 also facilitated TWEAK/
Fn14 signaling towards MAL translocation. Reduced ET-1
levels in Fn14-/- mice are probably due to reduced fibrosis
[10, 29].
RV failure is the leading cause of death in PAH [8, 38].
However, available therapies all target pulmonary vaso-
constriction, but not the remodeling of the right heart [12].
Fn14 combines several features that make it a good ther-
apeutic target: Fn14-/- mice are viable and show no
obvious phenotype under physiological conditions. Fn14 is
specifically upregulated in the RV after PAB, and its
genetic ablation protected from right heart disease. Thus,
global inhibition during therapy appears not prone to cause
side effects. However, it is possible that Fn14-/- mice
activate compensatory pathways. In that case, therapeutic
inhibition might have negative effects. For example, it has
recently been suggested, in contrast to previous reports,
that the human heart is a highly dynamic organ with the
ability to regenerate cardiomyocytes [22]. Thus, as
TWEAK has recently been shown to be a positive regulator
of cardiomyocytes proliferation [35], a therapy targeting
TWEAK/Fn14 signaling might interfere with cardiac
homeostasis and cause over adverse effect.
Anti-TWEAK blocking antibodies and Fn14-Fc decoy
receptor are available and have successfully been tested in
other disease models. Given our findings, blocking the
TWEAK/Fn14 axis may be a useful therapy for protecting
patients from right heart disease and therefore, warrants
further preclinical investigation.
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